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Background-—To determine whether daily physical activity (PA), as measured by implanted devices (through accelerometer
sensor), was related to the risk of developing atrial arrhythmias during long-term follow-up in a population of heart failure (HF)
patients with an implantable cardioverter defibrillator (ICD).
Methods and Results-—The study population was divided into 2 equally sized groups (PA cutoff point: 3.5 h/d) according to their
mean daily PA recorded by the device during the 30- to 60-day period post-ICD implantation. Propensity score matching was used
to compare 2 equally sized cohorts with similar characteristics between lower and higher activity patients. The primary end point
was time free from the first atrial high-rate episode (AHRE) of duration ≥6 minutes. Secondary end points were: first AHRE
≥6 hours, first AHRE ≥48 hours, and a combined end point of death or HF hospitalization. Data from 770 patients (6515 years;
66% men; left ventricular ejection fraction 3512%) remotely monitored for a median of 25 months were analyzed. A PA ≥3.5 h/d
was associated with a 38% relative reduction in the risk of AHRE ≥6 minutes (72-month cumulative survival: 75.0% versus 68.1%;
log rank P=0.025), and with a reduction in the risk of AHRE ≥6 hours, AHRE ≥48 hours, and the combined end point of death or HF
hospitalization (all P<0.05).
Conclusions-—In HF patients with ICD, a low level of daily PA was associated with a higher risk of atrial arrhythmias, regardless of
the patients’ baseline characteristics. In addition, a lower daily PA predicted death or HF hospitalization. ( J Am Heart Assoc.
2018;7:e008146. DOI: 10.1161/JAHA.117.008146.)
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A low level of daily physical activity (PA) is an independentpredictor of all-cause mortality, cardiovascular events,
and atrial fibrillation (AF) in the general population.1,2 Several
observations suggest that daily PA also predicts outcome in
various chronic diseases, including heart failure (HF).3–8
Information on PA is recorded and stored automatically by
many implantable cardioverter-defibrillators (ICDs) through
accelerometer sensors incorporated into the device. These
data provide an easily accessible quantitative measure that
may reflect the individual’s functional status.7,9 Previous
From the Cardiology Unit, “Card. G. Panico” Hospital, Tricase, Italy (P.P., Maria Z., M.A.); Cardiology and Arrhythmology Clinic, Marche Polytechnic University, University
Hospital “Umberto I—Lancisi—Salesi”, Ancona, Italy (F.G., F.D.U., A.C.); Department of Cardiology, Monaldi Hospital, Second University of Naples, Italy (E.A., G.N.);
Institute of Cardiology, University of Bologna, S.Orsola-Malpighi University Hospital, Bologna, Italy (Matteo Z); “Vito Fazzi” Hospital, Lecce, Italy (E.C.L.P.); Division of
Cardiology, University of Eastern Piedmont, Maggiore della Carita Hospital, Novara, Italy (G.D., E.O.); Cardiology—Coronary Care Unit, Pugliese-Ciaccio Hospital,
Catanzaro, Italy (V.A., G.M.); Department of Cardiovascular Diseases, San Filippo Neri Hospital, Rome, Italy (R.P.R.); Cardiology Department, University of Modena and
Reggio Emilia, Policlinico di Modena, Italy (G.B.).
*Dr Palmisano and Dr Guerra contributed equally to this study.
†A complete list of the Italian Association of Arrhythmology and Cardiac Pacing (AIAC) National Directive Board 2016-2018 members can be found in the appendix
at the end of the manuscript.
Correspondence to: Pietro Palmisano, MD, Via S. Pio X, 4 73039 Tricase (Le), Italy. E-mail: dr.palmisano@libero.it
Received December 26, 2017; accepted January 23, 2018.
ª 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is
non-commercial and no modifications or adaptations are made.
DOI: 10.1161/JAHA.117.008146 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on February 13, 2020
studies evaluating patient activity by means of ICDs, whether
alone7,8 or integrated with other diagnostics,10–12 in HF
patients have suggested an inverse relationship with survival,
after adjustment for other clinical factors. The relationship
between daily PA and the long-term risk of developing AF in
HF patients is unknown.
Remote monitoring (RM) enables the level of daily PA of
patients with implantable devices to be monitored over time.
In addition, it allows the continuous, rapid, and accurate
detection of AF episodes (including subclinical atrial high-rate
episodes [AHREs]), over long periods.13
The aim of the present study was to determine whether
daily PA, as measured by implanted devices, is related to the
risk of developing atrial arrhythmias during long-term follow-
up in a population of HF patients. A secondary aim was to
assess the relationship between daily PA and clinical
outcomes, such as death and HF.
Methods
The authors declare that all supporting data are available
within the article. IMPLANTED (The Italian Multicentre Obser-
vational Registry on Patients With Implantable Devices
Remotely Monitored) is a multicenter, retrospective registry
endorsed by the Italian Association of Arrhythmology and
Cardiac Pacing (AIAC), enrolling patients from 7 Italian high-
volume arrhythmia centers. All consecutive patients aged
≥18 years who underwent pacemaker or ICD implantation in
accordance with current guidelines14 from January 1, 2009, to
September 30, 2016, and followed up by means of RM in
addition to conventional in-office examination, were enrolled
in the registry.
The study was approved by Ethics Committees of all
participating institutions, and was registered on www.clinica
ltrials.gov under identifier NCT03061747. All patients gave
their written informed consent at the time of enrollment.
The data, analytic methods, and study materials will be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Population
For the purpose of this study, patients who met the following
inclusion criteria were included in the analysis: (1) implanta-
tion of an ICD with an atrial lead, and equipped with a
software platform for daily recording and uploading of patient
activity; (2) availability of complete data on daily PA collected
by the device in the period from 30 to 60 days after
implantation (activity window, see below); (3) availability of at
least 1 RM transmission (manual or automatic) performed not
earlier than 30 days after the end of the activity window. In
order to test the real effect of PA, patients were excluded
from the analysis if they already had at least 1 AHRE
(≥180 bpm atrial, documented by the ICD via its atrial lead
and stored digitally) of ≥6 minutes during the first 60 days
after implantation, and if they died or underwent another
hospitalization during the 30-day activity window.
Remote Monitoring
All patients enrolled in the study received an ICD equipped
with RM capabilities; 38.7% of patients were enrolled in the
Medtronic CareLink Network (Medtronic Inc, Minneapolis,
MN), 27.1% in the Boston Scientific Latitude Patient Manage-
ment System (Boston Scientific, St Paul, MN), 17.7% in the
Biotronik Home Monitoring system (Biotronik Gmbh, Berlin,
Germany), and 16.5% in the St Jude Medical Merlin.net system
(St Jude Medical, Sylmar, CA). These 4 RM systems operate in
a similar manner and have previously been described in
detail.4,12,13 Briefly, the remote system consists of a base
station that is placed in the patient’s home and is capable of
full device interrogation and transmission. These interroga-
tions may be patient initiated or (for some models) performed
automatically by wireless telemetry at scheduled intervals.
Data are then transferred by telephone line and are accessible
for routine clinical care through a secure website adminis-
tered by the manufacturer. In the case of devices with
wireless communication capabilities, the ICD allows unsched-
uled alert-based transmissions without patient intervention.
Specifically, in the case of programmable alert conditions, the
system can transmit data and notify the physician via phone
or e-mail. Each transmission contains the complete device
diagnostic information, including counts of arrhythmia
episodes and therapies, rhythm information, and technical
parameters.
All patients included in the registry were enrolled in the
remote follow-up program and performed a first successful
transmission within 3 months after implantation. The routine
Clinical Perspective
What Is New?
• In heart failure patients with implantable devices, a low level
of baseline daily physical activity as measured by the
devices (through the accelerometer sensor) was associated
with a higher risk of atrial arrhythmias.
• A low level of baseline physical activity was also associated
with a higher risk of death or heart failure hospitalization.
What Are the Clinical Implications?
• The data already available to physicians through physical
activity measurement could prove effective in foreseeing
atrial arrhythmic episodes and improving outcomes.
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remote transmissions were scheduled at intervals of 1 to
3 months, according to physician decision.
Device Measurement of Daily Physical Activity
The PA is measured by the device’s accelerometer sensor,
which is designed to capture normal daily activities, including
walking at a slow pace. The software platform for recording
daily PA operates in a similar manner for all manufacturers.
The accelerometer detects both the frequency and amplitude
of the patient’s motion and translates this into a proportional
electrical signal. The number of minutes during which the
patient is active per day is counted. A minute is considered
to be “active” if a threshold that incorporates both the
number and magnitude of deflections in the accelerometer
signal is reached. For the purpose of this study, the daily
time in which the patient was active was expressed in hours
per day.
All the devices implanted during the study period were
capable of storing up to 1 year of daily PA data. At each RM
transmission, all available activity data were uploaded.
The baseline daily PA was defined as the mean daily
activity (in h/d) recorded in the period from 30 to 60 days
after device implantation (this period was dubbed the “activity
window”) (Figure 1). This window was selected a priori to take
into account clinical recovery after the device implantation
procedure.7,8
Data Collection
Clinical history, cardiovascular risk factors, comorbidity,
cardiovascular medications, and ICD indications were col-
lected for all patients. Transthoracic echocardiography was
performed in all patients prior to ICD implantation.
A complete review of all remote transmissions was
performed for all patients, in order to calculate and record
the mean daily PA during the activity window, and to detect all
arrhythmic episodes from the end of the activity window to
the last available transmission. For the purpose of this study,
the time between the end of the activity window and the date
of the last available transmission was considered as the
observation period.
After implantation, in addition to undergoing RM, all
patients were followed up at their referring out-of-hospital
clinics on a 6- or 12-month basis, or earlier in case of
unscheduled visits.
Figure 1. Two examples of calculation of baseline daily physical activity (PA). Baseline daily PA was
calculated as the mean daily activity (in h/d) recorded in the period from 30 to 60 days after device
implantation (activity window). A, Patient enrolled in the Boston Scientific Latitude Patient Management
System (Boston Scientific, St Paul, MN). The mean daily PA recorded during the activity window was 1.2 h/d
(lower-activity patient). B, Patients enrolled in the Medtronic CareLink Network (Medtronic Inc, Minneapolis,
MN). The mean daily PA recorded during the activity window was 4.8 h/d (higher-activity patient).
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Information about clinical outcomes such as hospitaliza-
tions, deaths, and causes of death were collected during
hospital visits or by phone calls for patients who missed
programmed visits.
Deaths were classified according to a modified
Hinkle-Thaler classification,15 and categorized into 3 prede-
fined groups: non–sudden cardiac death (further categorized
into HF death, coronary death, and cardiac death but
unable to classify further), noncardiac death, and sudden
death.
Data regarding ICD implantation, baseline characteristics
of patients, and clinical outcomes were collected prospec-
tively at the enrolling centers and retrospectively analyzed for
the purpose of this study.
End Points
The primary end point was the time free from first AHRE of
≥6 minutes. This cutoff was based on previous evidence,
which defined 6-minute episodes as significantly associated
with an increased risk of strokes and thromboembolic
events.16,17 Secondary end points were (1) time free from
first AHRE ≥6 hours; (2) time free from first AHRE ≥48 hours;
(3) time free from a predefined combined end point of death
and HF hospitalization; (4) time free from all-cause death; and
(5) time free from HF hospitalization.
Only hospitalizations requiring at least 1 overnight stay,
and which were adjudicated as related to HF by a blinded
Endpoint Advisory Committee contributed to the end point.
Statistical Analysis
Descriptive statistics are reported as meanstandard devia-
tion for normally distributed continuous variables and com-
pared by means of Student t test and analysis of variance.
Continuous variables with skewed distribution are reported as
medians with 25th to 75th percentiles. Categorical data are
expressed as percentages, reported in contingency tables and
compared by means of v2 test or Fisher exact test, as
appropriate. Relative risks are reported with their 95%
confidence intervals.
The effect of individual variables on the risk of AHRE
≥6 minutes was investigated by using univariate Cox propor-
tional hazards models applied to the whole study population.
Variables that showed an effect on the risk of AHRE
≥6 minutes with a significance level <0.2 on univariate
analyses were entered into multivariable Cox proportional
hazards models. Cox model findings are presented as hazard
ratios (HRs), tests of significance, and 95% confidence
intervals (CIs). In this model, daily PA was considered as a
continuous variable. Interactions between the covariates were
tested for significance in the model.
Subsequently, in order to assess the relationship between
daily PA and study end points, all patients were stratified into
2 equal-sized groups on the basis of their mean daily PA value
recorded during the 30- to 60-day window post-ICD implan-
tation, with a cut point of 3.5 h/d (median). A propensity
score for the likelihood of lower daily PA was obtained by
means of multiple logistic regression. The variables included
in the score were age, left ventricular ejection fraction (LVEF),
New York Heart Association (NYHA) class, CHA2DS2-VASC2
score, ischemic cardiomyopathy, other cardiac structural
diseases, secondary prevention, history of AF, diabetes,
chronic renal disease, obstructive sleep apnea, previous
stroke or transient ischemic attack, coronary artery disease,
previous coronary arterial bypass graft, medical therapy with
angiotensin-converting enzyme inhibitors, angiotensin recep-
tor blockers, furosemide, antiplatelets, ivabradine, mineralo-
corticoid receptor antagonists, amiodarone, and other
antiarrhythmic drugs. Matching was then performed on log-
transformed propensity score in a 1:1 fashion with a caliper of
0.1,to take into account the differences in baseline charac-
teristics between patients with low and high daily PA. Kaplan-
Meier analyses and a log rank P test were used to compare
the end points between the 2 patient groups. P values of
<0.05 were considered statistically significant. The data were
analyzed by means of the statistical software package
Statistica version 6.1 (StatSoft Inc, Tulsa, OK).
Results
General Population
Of the 1107 patients enrolled in the IMPLANTED registry, 770
were eligible for analysis (Figure 2).
Table 1 shows the baseline characteristics of the general
population stratified into 2 groups according to daily PA, and
the propensity score-matched groups.
Data on daily PA recorded in the 30- to 60-day window post-
ICD implantation was available for all enrolled patients and
averaged 3.83.4 h/d. Lower-activity patients were on aver-
age 10 years older, presented a worse NYHA class, had a
higher CHA2DS2-VASC2 score, and presented a lower LVEF on
enrollment. They were more likely to receive cardiac resyn-
chronization therapy combined with ICD, and to have an
ischemic cardiomyopathy. They also had more concomitant
diseases such as diabetes mellitus, chronic renal disease, and
previous stroke or TIA. Lower-activity patients were more often
treated with furosemide, mineralocorticoid receptor antago-
nists, amiodarone, and other antiarrhythmic drugs (Table 1).
During a median follow-up of 25 months (first to third
quartile, 12–50 months), the numbers of patients who expe-
rienced at least 1 AHRE of duration ≥6 minutes, ≥6 hours and
≥48 hours were 88 (11.4%), 83 (10.8%) and 61 (7.9%),
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respectively. The number of deaths and HF hospitalizations
recorded was 35 (2.7%) and 111 (14.4%), respectively.
In the study population, univariate analysis showed that an
higher daily PA was significantly associated with lower risk of
at least 1 AHRE ≥6 minutes during follow-up. Patient factors
associated with greater risk of AHRE ≥6 minutes on univariate
analysis were higher age, higher NYHA class, higher
CHA2DS2-VASc score, cardiac resynchronization therapy,
chronic renal failure, history of paroxysmal/persistent AF,
and the use of amiodarone. Conversely, a higher LVEF was
associated with lower risk of AHRE ≥6 minutes (Table 2).
After multivariable analysis, the predictive factors that were
still associated with greater risk of AHRE ≥6 minutes were
higher age and a history of paroxysmal/persistent AF. A
higher LVEF and a higher daily PA remained associated with
lower risk of AHRE ≥6 minutes. Interactions among the
covariates were not significant.
According to quintiles of daily PA, patients of the whole
study population were divided into 5 groups: <2.0 h/d
(n=154); from 2.0 to 2.9 h/d (n=154); from 3.0 to 4.0 h/d
(n=154); from 4.1 to 5.9 h/d (n=154); and >5.9 h/d (n=154).
Figure 3 shows a forest plot displaying HRs for primary end
point of the 5 groups after multivariable analysis.
Propensity Score–Matched Groups
After propensity score matching for the likelihood of having a
lower daily PA, we selected 223 lower-activity and 223 higher-
activity patients with similar baseline characteristics on 35
variables.
A baseline daily PA ≥3.5 h/d was significantly associated
with a 38% relative reduction of risk of the primary end point
(first AHRE ≥6 minutes) (relative risk [RR]=0.62; 95% CI,
0.41–0.95; P=0.025). There were also significant associa-
tions with first AHRE ≥6 hours (RR=0.58; 95% CI, 0.34–0.99;
P=0.040), first AHRE ≥48 hours (RR=0.48; 95% CI, 0.24–
0.96; P=0.033), the combined end point of death or HF
hospitalization (RR=0.66; 95% CI, 0.44–0.98; P=0.039), and
first HF hospitalization (RR=0.61; 95% CI, 0.37–0.99;
P=0.041).
Figure 4 shows event-free survival at 72 months with
patients stratified into 2 equal-sized groups according to
baseline daily PA (cut point 3.5 h/d). Survival from the
primary end point was 75.0% for higher-activity patients and
68.1% for lower-activity patients (log rank P=0.025) (Fig-
ure 4A). Survival from first AHRE ≥6 hours was 81.5% for
higher-activity patients and 75.9% for lower-activity patients
(log rank P=0.048) (Figure 4B). Survival from first AHRE
≥48 hours was 87.3% for higher-activity patients and 81.7%
for lower-activity patients (log rank P=0.042) (Figure 4C).
Survival from the combined end point of death and HF
hospitalization was 78.1% for higher-activity patients and
67.2% for lower-activity patients (log rank P=0.038)
(Figure 4D). Survival from all-cause death was 94.1% for
higher-activity patients and 84.7% for lower-activity patients
(log rank P=0.143) (Figure 4E). Survival from first HF
hospitalization was 87.0% for higher-activity patients and
72.4% for lower-activity patients (log rank P=0.048)
(Figure 4F).
Discussion
The main finding of the present study is that the daily PA
measured by the accelerometer sensor of implanted ICDs
over a 30-day window starting 30 days after implantation
predicted the risk of AHREs detected by the device in patients
with HF. The association between daily PA and risk of AHREs
was independent of the baseline characteristics of patients.
Several studies have examined the association between PA
and risk of AF, and have demonstrated that in the general
population a regular PA seems to have a protective role in
development of AF.18,19 A recent analysis enrolling a large,
multiethnic cohort of individuals undergoing a graded exercise
treadmill test, demonstrated an inverse association between
cardiorespiratory fitness status and risk of incident AF.2 In
addition, epidemiological studies have shown that there is a
close correlation between a low level of daily PA, obesity, and
increased risk of AF.2,18,20 The relationship between PA and
AF in patients with HF and ICD has not been previously
investigated.
Figure 2. Study flow with derivation of the study population. AF
indicates atrial fibrillation; AHRE, atrial high-rate episode; ICD,
implantable cardioverter defibrillator; IMPLANTED, Italian Multi-
centre Observational Registry on Patients With Implantable
Devices Remotely Monitored.
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Table 1. Baseline Characteristics of Patients Subdivided According to h/d Physical Activity Measured by the Device
Characteristics
General Population Propensity Score Matched
Low Activity
(<3.5 h/d)
(n=387)
High Activity
(≥3.5 h/d)
(n=383) P Value
Low Activity
(<3.5 h/d)
(n=223)
High Activity
(≥3.5 h/d)
(n=223) P Value
Baseline characteristics
Male, n (%) 251 (64.9) 260 (67.9) 0.374 133 (59.6) 141 (63.2) 0.436
Age, y, mean+SD 70.112.5 60.814.0 <0.001 66.413.1 64.413 0.105
LVEF in %, meanSD 34.411.0 36.213.2 0.034 35.411.8 35.112.3 0.839
Mean (SD) NYHA class 2.20.8 2.00.7 <0.001 2.00.7 2.00.7 0.838
NYHA class, n (%) <0.001 0.998
I 56 (14.5) 72 (18.8) 39 (17.5) 38 (17.0)
II 208 (53.7) 243 (63.4) 136 (61.0) 138 (61.9)
III 114 (29.5) 66 (17.2) 47 (21.1) 46 (20.6)
IV 9 (2.3) 2 (0.5) 1 (0.4) 1 (0.4)
CHA2DS2-VASc score, meanSD 41.5 3.11.6 <0.001 3.61.6 3.41.6 0.192
CHA2DS2-VASc score, n (%) <0.001 0.346
0 (low risk) 6 (1.6) 19 (5.0) 4 (1.8) 8 (3.6)
1 (intermediate risk) 22 (5.7) 57 (14.9) 19 (8.5) 24 (10.8)
2 to 9 (high risk) 359 (92.8) 307 (80.2) 200 (89.7) 191 (85.7)
Cardiac resynchronization
therapy, n (%)
233 (60.2) 168 (43.9) <0.001 104 (46.6) 104 (46.6) 1.000
Daily physical activity in h/d,
meanSD
2.10.9 6.33.7 <0.001 2.10.9 5.52.2 <0.001
Etiology, n (%) 0.005 0.232
Ischemic cardiomyopathy 193 (49.9) 154 (40.2) 103 (46.2) 87 (39.0)
Nonischemic cardiomyopathy 146 (37.7) 154 (40.2) 84 (37.7) 101 (45.3)
Other 48 (12.4) 75 (19.6) 36 (16.1) 35 (15.7)
Indication for ICD, n (%) 0.009 0.842
Primary prevention 350 (90.5) 365 (95.3) 209 (93.7) 210 (94.2)
Secondary prevention 37 (9.6) 18 (4.7) 14 (6.3) 13 (5.8)
Associated disorders
Arterial hypertension, n (%) 294 (76.0) 276 (72.1) 0.216 160 (71.7) 163 (73.1) 0.751
Diabetes mellitus, n (%) 145 (37.5) 118 (30.8) 0.051 77 (34.5) 71 (31.8) 0.546
Dyslipidemia, n (%) 243 (62.8) 233 (60.8) 0.577 137 (61.4) 134 (60.1) 0.771
Obesity, n (%) 108 (27.9) 119 (31.1) 0.336 72 (32.3) 63 (28.3) 0.353
Chronic renal disease, n (%) 134 (34.6) 71 (18.5) <0.001 53 (23.8) 49 (22.0) 0.652
COPD, n (%) 97 (25.1) 105 (27.4) 0.459 59 (26.5) 60 (26.9) 0.915
Obstructive sleep apnea, n (%) 46 (11.9) 28 (7.3) 0.031 22 (9.9) 16 (7.2) 0.309
Previous stroke/TIA, n (%) 35 (9.0) 18 (4.7) 0.017 18 (8.1) 11 (4.9) 0.179
Paroxysmal/persistent AF, n (%) 59 (15.2) 54 (14.1) 0.653 30 (13.5) 33 (14.8) 0.683
CAD, n (%) 181 (46.8) 140 (36.6) 0.004 96 (43.0) 82 (36.8) 0.176
Previous PCI n (%) 106 (27.4) 120 (31.3) 0.230 57 (25.6) 64 (28.7) 0.456
Previous CABG n (%) 85 (22.0) 47 (12.3) <0.001 37 (16.6) 26 (11.7) 0.135
Continued
DOI: 10.1161/JAHA.117.008146 Journal of the American Heart Association 6
Physical Activity and Risk of Atrial Arrhythmias Palmisano et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on February 13, 2020
Patients with defibrillators are at high risk of atrial
arrhythmias, particularly AF, which predispose them to
embolic events and worsening congestive HF, with a negative
prognostic impact.21–25 Atrial arrhythmias can also trigger
inappropriate shocks.25
Modern cardiac implantable devices with implanted atrial
lead, through analytic software allow the continuous detection
and characterization of individual AHREs over long periods.
Studies have indicated that the detection of such episodes
correlates well with electrocardiographic documentation of
AF. Subclinical atrial tachyarrhythmias detected by implan-
table devices, even if of short duration, are associated with a
significantly increased risk of ischemic stroke or systemic
embolism16,17,26 and are independent predictors of cardio-
vascular mortality.27,28 For these reasons, the prevention
and/or reduction of atrial arrhythmias is an important goal in
the management of patients with HF and ICD.
ICDs and CRT devices are routinely equipped with
activity sensors in order to adjust heart rates during
patient activity. Thus, data on daily PA assessed by these
Table 1. Continued
Characteristics
General Population Propensity Score Matched
Low Activity
(<3.5 h/d)
(n=387)
High Activity
(≥3.5 h/d)
(n=383) P Value
Low Activity
(<3.5 h/d)
(n=223)
High Activity
(≥3.5 h/d)
(n=223) P Value
Cardiovascular medications
Beta-blockers, n (%) 364 (94.1) 355 (92.7) 0.446 210 (94.2) 206 (92.4) 0.450
ACE-Is/ARBs, n (%) 309 (79.8) 322 (84.1) 0.127 197 (88.3) 198 (88.8) 0.882
Furosemide, n (%) 325 (84.0) 267 (69.7) <0.001 182 (81.6) 183 (82.1) 0.902
Statins, n (%) 219 (56.6) 215 (56.1) 0.899 132 (59.2) 125 (56.1) 0.502
Antiplatelet drugs, n (%) 258 (66.7) 272 (71.0) 0.192 159 (71.3) 158 (70.9) 0.917
Ivabradine, n (%) 32 (8.3) 55 (14.4) 0.008 22 (9.9) 21 (9.4) 0.873
MRAs, n (%) 239 (61.8) 212 (55.4) 0.071 129 (57.8) 147 (65.9) 0.079
Amiodarone, n (%) 127 (32.8) 83 (21.7) <0.001 64 (28.7) 49 (22.0) 0.102
Oral anticoagulants, n (%) 83 (21.4) 69 (18.0) 0.232 47 (21.1) 43 (19.3) 0.637
Digoxin, n (%) 27 (7.0) 24 (6.3) 0.692 15 (6.7) 13 (5.8) 0.696
Other AADs, n (%) 3 (0.8) 7 (1.8) 0.197 2 (0.9) 5 (2.2) 0.253
AAD indicates antiarrhythmic drug; ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CABG, coronary arterial bypass graft; COPD,
chronic obstructive pulmonary disease; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York
Heart Association; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.
Table 2. Predictors of AHRE Lasting ≥6 Minutes in the Overall Study Population (n=770): Univariate and Multivariable Cox
Proportional Hazards Analysis
Variable
Univariable Analysis Multivariable Analysis
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Age (per 1-y increase) 1.035 (1.02–1.06) <0.001 1.047 (1.02–1.08) 0.003
Left ventricular ejection fraction (per 1% increase) 0.977 (0.96–0.99) 0.031 0.904 (0.84–0.98) 0.011
NYHA class (per 1 increase) 1.620 (1.18–2.22) 0.003 1.158 (0.78–1.71) 0.460
CHA2DS2-VASc score (per 1 increase) 1.216 (1.06–1.41) 0.007 0.962 (0.77–1.19) 0.724
Cardiac resynchronization therapy 2.010 (1.26–3.21) 0.004 1.540 (0.91–2.61) 0.108
Daily physical activity (per 1 h/d increase) 0.997 (0.99–0.99) <0.001 0.998 (0.99–0.99) 0.007
Chronic renal failure 1.668 (1.05–2.66) 0.032 0.833 (0.48–1.43) 0.507
Paroxysmal/persistent AF 5.312 (3.33–8.48) <0.001 4.039 (2.45–6.65) <0.001
Amiodarone 2.490 (1.58–3.92) <0.001 1.828 (0.87–3.84) 0.111
AF indicates atrial fibrillation; AHRE, atrial high-rate episode; CI, confidence interval; NYHA, New York Heart Association.
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sensors can easily be obtained on ICD/CRT interrogation
(remote or in-office), and it correlates strongly with data
obtained from validated external accelerometers.28 This
information is available irrespective of the activation of the
rate response function.
The results of our study suggest that the level of daily PA
measured by implanted devices predicts the risk of episodes
of atrial arrhythmias detected by the device. Specifically, we
found a significant association both with short and subclinical
episodes and with those of longer duration (>6 and
>48 hours) requiring clinical intervention. The results of the
study do not provide a definite explanation for these findings.
It is possible that daily PA is a clinical status marker, and that
a lower level of daily PA identifies the most compromised
patients, who have a higher risk of developing atrial arrhyth-
mias. It is also possible that a lower level of PA has a negative
influence on cardiovascular risk factors, thereby increasing
the risk of atrial arrhythmias. Because AF has multiple
cardiovascular and noncardiovascular risk factors, the reduc-
tion in the risk of AF in patients with higher level of daily PA
may be partly mediated through the improvement of preex-
isting risk factors. Previous studies showed that higher
physical fitness is associated with a lower level of inflamma-
tory markers (eg, C-reactive protein).29 Thus, it is likely that
the reduction in the risk of AF at a higher level of daily PA is
partly mediated through reducing the incidence of inflamma-
tion. Overweight and obesity are also important risk factors
for AF2,18,20 and may induce AF by increasing left atrial size
and volume.30 It is therefore likely that the inverse association
between PA and AF is also mediated through the regulation of
body mass index.
The results of several studies on ICD patients have shown
that a reduction in daily PA level detected by device identifies
patients at a higher risk of HF hospitalizations within the
subsequent month.10–12 In addition, a baseline low daily PA
measured by implantable devices after implantation is a
Figure 3. Forest plot showing the risk of AHREs lasting
≥6 minutes in the whole study population (n=770) by quintiles
of daily physical activity after multivariable analysis. AHRE
indicates atrial high-rate episode; CI, confidence interval; HR,
hazard ratio.
Figure 4. Kaplan-Meier estimates of the cumulative time free from first atrial high-rate episodes (AHREs) detected by the device, and from
clinical events in the low and high physical activity propensity score–matched groups (n=446). A, First AHRE lasting ≥6 minutes. B, First AHRE
lasting ≥6 hours. C, First AHRE lasting ≥48 hours. D, All-cause death or heart failure (HF) hospitalization. E, All-cause death. F, HF
hospitalization. Events are counted after closure of the activity window used to determine baseline physical activity level.
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strong predictor of negative long-term outcomes, being
associated with higher all-cause mortality and higher risk of
HF hospitalization.7,8 The results of the present study
confirmed this evidence, as a baseline daily PA <3.5 h/d
was significantly associated with a higher risk of death or HF
hospitalization and of HF hospitalization alone, even after
correction for disease severity.
Study Limitations
Although data were collected prospectively at the enrolling
centers for an observational registry, the analysis performed
was retrospective and is therefore subject to all of the
limitations of a retrospective analysis. Moreover, while
propensity score matching is one of the best techniques in
order to reduce the intrinsic biases of nonrandomized
studies, our results should be interpreted with caution, as
confounding factors cannot be entirely excluded. Moreover,
further prospective, large-population analyses are needed to
confirm them. In addition, the definition of our activity
window from 30 to 60 days postimplantation is (although
based on common sense) arbitrary, and different periods
could have provided slightly different results. Moreover,
extending our results to a broader HF population with
dissimilar baseline characteristics and to non-ICD recipients
is not warranted.
In contrast with previous similar studies,7,8 the reduced
risk for all-cause mortality associated with a lower level of
daily PA did not reach statistical significance (Figure 4E). It is
likely that statistical significance has not been reached due to
the small sample size, the low number of events, and the
relative short duration of follow-up.
Finally, while modern implantable devices offer a reliable
and sensitive mean of detecting both subclinical arrhythmias
and PA, different manufacturers may be slightly different in
function and related software, thus yielding slightly different
measurements.
Conclusions
In HF patients with implantable devices, a low level of baseline
daily PA was associated with a higher risk of atrial arrhyth-
mias, regardless of the baseline characteristics of the
patients. In addition, a lower daily PA predicted death or HF
hospitalization, as well as HF hospitalization alone.
The data already available to physicians through PA
measurement could prove effective in foreseeing arrhythmic
episodes, thus helping in reducing mortality and HF hospital-
izations in patients with implantable devices. Further research
is needed in order to confirm the present findings and to
understand the possible mechanisms underlying our
observations.
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